Episurf Medical
-
Extremities
Prospective Episealer® Talus clinical study fully recruited
September 13, 2023 – Episurf Medical (Nasdaq: EPIS B) today announces that all patients have been recruited to a prospective…
Read More » -
Regulatory
Episurf Medical receives FDA 510(k) clearance for Episealer® Patellofemoral System
December 27, 2022- Episurf Medical (NASDAQ: EPIS B) today announces that the company has received 510(k) clearance from the US…
Read More » -
Regulatory
Episurf Medical reaches important regulatory milestone in India
December 14, 2022 – Episurf Medical (Nasdaq: EPIS B) today announces that the Indian authorities have, through their Directorate General…
Read More » -
Recon
Episealer® Patellofemoral System – planned 510(k) submission in Q4 2021
FRI, FEB 19, 2021 08:00 CET Episurf Medical (Nasdaq: EPIS B) today announces that the company intends to submit a…
Read More » -
Recon
Episurf Medical reaches milestone of 800 implants
MON, AUG 24, 2020 08:30 CET Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone…
Read More » -
Recon
First Korean patent approval for Episurf Medical
THU, MAY 28, 2020 12:15 CET Episurf Medical (NASDAQ: EPIS B) has received a Notice of Allowance from the Korean…
Read More » -
Recon
Positive results from follow-up of 30 patients in a Swedish multicentre clinical trial of the Episealer® Knee implant
Episurf Medical (Nasdaq: EPIS B) March 8, 2020 – Today announces that results from a clinical study with follow-up of…
Read More » -
Recon
Episurf Medical reaches milestone of 700 implants
FRI, FEB 21, 2020 09:05 CET Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone…
Read More » -
Recon
Episurf Medical reaches milestone of 600 implants
WED, SEP 18, 2019 Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the…
Read More » -
Recon
Episurf Medical reaches new milestones in its patient population
August 16, 2019 Episurf Medical (Nasdaq: EPIS B) today announces that the company has reached new milestones in its patient…
Read More » -
Extremities
Episurf Medical reaches milestone of 500 implants
Feb 20, 2019 Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of the 500th surgery…
Read More » -
Hospitals
Episurf Medical has received initial feedback from the US FDA on the IDE application for the Episealer® knee implant
MON, JUL 30, 2018 08:30 CET Episurf Medical (NASDAQ: EPIS B) today announces that the company has received initial feedback…
Read More » -
Hospitals
Episurf Medical submits IDE application to the US FDA for the Episealer® knee implant
JUN 28, 2018 Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached an important milestone on its…
Read More » -
Extremities
Episurf Medical enters into distribution agreement in Hong Kong and establishes subsidiary in the US
APR 26, 2018 Episurf Medical (NASDAQ: EPIS B) today announces that the company has entered into a distribution agreement in…
Read More » -
Hospitals
Episurf Medical’s knee products approved for marketing and sale in Spain
TUE, APR 03, 2018 Episurf Medical (NASDAQ: EPIS B) today announces that the Spanish authority AEMPS (Agencia Española de Medicamentos…
Read More »